Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery
NCT ID: NCT02329743
Last Updated: 2019-02-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
256 participants
INTERVENTIONAL
2014-12-31
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
NCT05147233
RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
NCT02065375
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
NCT04089735
Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery
NCT04739709
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
NCT05626478
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RX-10045 0.05% nanomicellar solution
topical eye drops
RX-10045
topical therapy
RX-10045 0.1% nanomicellar solution
topical eye drops
RX-10045
topical therapy
Vehicle
topical eye drops
RX-10045
topical therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RX-10045
topical therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Refractive surgery in the study eye within the past 2 years
* History or presence of noninfectious inflammatory ocular disease (e.g., episcleritis, scleritis, uveitis) in either eye
* Intraocular pressure of \> 21 mm Hg in either eye
* Proliferative or severe nonproliferative diabetic retinopathy in either eye
* Neovascular/wet age-related macular degeneration in either eye
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
A.T. Resolve SARL
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tomasz Sablinski, MD
Role: STUDY_DIRECTOR
Auven Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Auven Therapeutics
Murray Hill, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ATR-45-1401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.